ARTICLE | Company News
Medical Marketing, King's College deal
February 7, 2005 8:00 AM UTC
The parties expanded their Viratis Ltd. JV to include the development of an HBV compound that uses the college's ribozyme technology. Viratis' VIR 5100 series of ribozymal-based therapies are in precl...